Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway

Carcinogenesis

Volumn 33, Issue 12, 2012, Pages 2391-2397

  Iwaya, Takeshi ^a,b   Yokobori, Takehiko ^c   Nishida, Naohiro ^a   Kogo, Ryunosuke ^a   Sudo, Tomoya ^a   Tanaka, Fumiaki ^a   Shibata, Kohei ^a   Sawada, Genta ^a   Takahashi, Yusuke ^a   Ishibashi, Masahisa ^a   Wakabayashi, Go ^b   Mori, Masaki ^d   Mimori, Koshi ^a  

^a KYUSHU UNIVERSITY BEPPU HOSPITAL   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MICRORNA; MICRORNA 144; RAPAMYCIN; RICTOR PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL FEATURE; COLORECTAL CANCER; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER METASTASIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DOWN-REGULATION; HT29 CELLS; HUMANS; MICRORNAS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84870328663     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs288     Document Type: Article

References (28)

1. Vivanco, I. et al. (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2, 489-501.
2. Guertin, D.A. et al. (2007) Defining the role of mTOR in cancer. Cancer Cell, 12, 9-22.
3. Motzer, R.J. et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 372, 449-456.
4. Ellard, S.L. et al. (2009) Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J. Clin. Oncol., 27, 4536-4541.
5. Doi, T. et al. (2010) Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J. Clin. Oncol., 28, 1904-1910.
6. Yao, J.C. et al. (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med., 364, 514-523.
7. Zhu, A.X. et al. (2011) Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer, 117, 5094-5102.
8. Witzig, T.E. et al. (2011) A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia, 25, 341-347.
9. Roy, H.K. et al. (2002) AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis, 23, 201-205.
10. Zhang, Y.J. et al. (2009) mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann. Surg. Oncol., 16, 2617-2628.
11. Gulhati, P. et al. (2011) mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res., 71, 3246-3256.
12. Gulhati, P. et al. (2009) Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin. Cancer Res., 15, 7207-7216.
13. Calin, G.A. et al. (2006) MicroRNA signatures in human cancers. Nat. Rev. Cancer, 6, 857-866.
14. Volinia, S. et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A., 103, 2257-2261.
15. Nishida, N. et al. (2011) MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin. Cancer Res., 17, 2725-2733.
16. Nishida, K. et al. (2005) Global analysis of altered gene expressions during the process of esophageal squamous cell carcinogenesis in the rat: a study combined with a laser microdissection and a cDNA microarray. Cancer Res., 65, 401-409.
17. Mori, M. et al. (2002) Analysis of the gene-expression profile regarding the progression of human gastric carcinoma. Surgery, 131(1 suppl.), S39-S47.
18. Quackenbush, J. (2002) Microarray data normalization and transformation. Nat. Genet., 32(suppl.), 496-501.
19. Kalimutho, M. et al. (2011) Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J. Gastroenterol., 46, 1391-1402.
20. Rasmussen, K.D. et al. (2010) The miR-144/451 locus is required for erythroid homeostasis. J. Exp. Med., 207, 1351-1358.
21. Cheloufi, S. et al. (2010) A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature, 465, 584-589.
22. Wang, W. et al. (2011) Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets. Int. J. Cancer, 129, 1624-1634.
23. Sureban, S.M. et al. (2011) DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res., 71, 2328-2338.
24. Moss, S.C. et al. (2010) Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1. J. Biol. Chem., 285, 11991-11997.
25. Masri, J. et al. (2007) mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res., 67, 11712-11720.
26. Allegra, C. et al. (2007) End points in advanced colon cancer clinical trials: a review and proposal. J. Clin. Oncol., 25, 3572-3575.
27. Chang, G.J. et al. (2007) Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J. Natl. Cancer Inst., 99, 433-441.
28. Mamounas, E. et al. (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J. Clin. Oncol., 17, 1349-1355.